Literature DB >> 28510630

Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach.

Stela Vujosevic1, Rafael Simó2.   

Abstract

Purpose: To review the usefulness of local and systemic inflammatory biomarkers of diabetic retinopathy (DR) to implement a more personalized treatment.
Methods: An integrated research (from ophthalmologist and diabetologist point of view) of most significant literature on serum, vitreous, and aqueous humor (AH) biochemical biomarkers related to inflammation at early and advanced stages of DR (including diabetic macular edema [DME] and proliferative DR) was performed. Moreover, novel imaging retinal biomarkers of local "inflammatory condition" were described.
Results: Multiple inflammatory cytokines and chemokines are increased in DR in both serum as well as in the eye (vitreous and AH). Nevertheless, local rather than systemic production of proinflammatory cytokines seems more relevant in the pathogenesis of both DR and DME. In the eye, retinal glia cells (macroglia and microglia) together with RPE are major sources of proinflammatory and angiogenic modulators. Retinal imaging allows for noninvasive clinical evaluation of retinal inflammatory response induced by diabetes mellitus. Conclusions: Proinflammatory cytokines/chemokines play an essential role in the pathogenesis of DR. Therefore, circulating biomarkers and retinal imaging aimed at assessing inflammation have emerged as useful tools for monitoring the onset and progression of DR. In addition, "liquid biopsy" of AH seems a good option in patients with advanced stages of DR requiring intravitreous injections. This strategy may permit us to implement a more personalized treatment with better visual function outcome. Further evaluation and validation of circulating and local biomarkers, as well as multimodal imaging is needed to gain new insights into this issue.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28510630     DOI: 10.1167/iovs.17-21769

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  37 in total

1.  Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema.

Authors:  Marc Figueras-Roca; Jessica Matas; Víctor Llorens; Anna Sala-Puigdollers; Manuel Navarro; Javier Zarranz-Ventura; Alfredo Adán; Blanca Molins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-12       Impact factor: 3.117

Review 2.  Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes.

Authors:  Christian Herder; Norbert Hermanns
Journal:  Semin Immunopathol       Date:  2019-02-18       Impact factor: 9.623

3.  Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema.

Authors:  Emilia Maggio; Maurizio Mete; Mauro Sartore; Francesco Bauci; Massimo Guerriero; Antonio Polito; Grazia Pertile
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-18       Impact factor: 3.117

4.  Elevated Retinol Binding Protein 3 Concentrations Are Associated With Decreased Vitreous Inflammatory Cytokines, VEGF, and Progression of Diabetic Retinopathy.

Authors:  Ward Fickweiler; Hyunseok Park; Kyoungmin Park; Margalit G Mitzner; Tanvi Chokshi; Tahani Boumenna; John Gautier; Yumi Zaitsu; I-Hsien Wu; Jerry Cavallerano; Lloyd P Aiello; Jennifer K Sun; George L King
Journal:  Diabetes Care       Date:  2022-09-01       Impact factor: 17.152

Review 5.  Current understanding of the molecular and cellular pathology of diabetic retinopathy.

Authors:  David A Antonetti; Paolo S Silva; Alan W Stitt
Journal:  Nat Rev Endocrinol       Date:  2021-01-19       Impact factor: 47.564

6.  Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System.

Authors:  Maurizio Cammalleri; Massimo Dal Monte; Filippo Locri; Stefania Marsili; Liliana Lista; Mario De Rosa; Vincenzo Pavone; Dario Rusciano; Paola Bagnoli
Journal:  J Diabetes Res       Date:  2017-12-31       Impact factor: 4.011

Review 7.  Pharmacological agents in development for diabetic macular edema.

Authors:  Mohammad Ali Sadiq; Muhammad Sohail Halim; Muhammad Hassan; Neil Onghanseng; Irmak Karaca; Aniruddha Agarwal; Rubbia Afridi; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Int J Retina Vitreous       Date:  2020-07-08

8.  HspB4/αA-Crystallin Modulates Neuroinflammation in the Retina via the Stress-Specific Inflammatory Pathways.

Authors:  Madhu Nath; Yang Shan; Angela M Myers; Patrice Elie Fort
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

9.  Ocular TGF-β, Matrix Metalloproteinases, and TIMP-1 Increase with the Development and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus.

Authors:  Lucia Saucedo; Isabel B Pfister; Souska Zandi; Christin Gerhardt; Justus G Garweg
Journal:  Mediators Inflamm       Date:  2021-06-25       Impact factor: 4.711

10.  Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations.

Authors:  Yousof Taghavi; Gholamhossein Hassanshahi; Nicholas G Kounis; Ioanna Koniari; Hossein Khorramdelazad
Journal:  J Cell Commun Signal       Date:  2019-01-03       Impact factor: 5.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.